Next-generation sickle cell readouts at ASH: Data Byte

The move toward sickle cell disease therapies that address the pathology’s root causes is reflected in promising early-stage readouts at ASH, which include both disease event rates and changes in red blood cell biology.

The momentum generated by last year’s approvals of sickle cell therapies from Novartis AG (NYSE:NVS; SIX:NOVN) and Global Blood Therapeutics Inc. (NASDAQ:GBT) continues via the progress made by next-wave candidates exploiting new modalities and candidates...